Logistics & Transportation

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

The EQUIP-A-Pharma program will combine Battelle’s synthesis platform and Aprecia’s 3D printing technology to produce APIs and finished drugs at the same site, aiming to strengthen US pharma supply resilience and support essential medicines.

Battelle and Aprecia Partner With HHS and DARPA to Advance Agile Drug Manufacturing

Videos

In the second part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, explains how wide regional price gaps and lack of visibility in global distribution create openings for counterfeit sellers—with many now specializing in categories like oncology—who exploit platforms such as Facebook and Instagram to market fake drugs.

Counterfeiters Target Fragmented Pharma Supply Chains Through Digital Marketplaces

In the eighth part of this roundtable discussion, supply chain experts emphasize that effective manufacturing strategies depend on product type, market location, and regulatory complexity, requiring a careful balance between outsourcing, internal production, regional distribution, and patient-centric priorities.

Peer Exchange: Pharma Leaders Stress Tailored, Balanced Approach to Long-Term Manufacturing Strategy (Episode 8)

Podcasts

This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price increase for Mounjaro in the UK, and long-term research confirming the safety of aluminum in childhood vaccines.

Pharma Pulse: US API Stockpile Plan, Mounjaro Price Hike in UK, and New Data on Vaccine Safety

In the August issue of Pharmaceutical Commerce, dive into the vital role of drug wholesalers in today's complex pharma supply chain, along with content spotlighting evolving challenges patients face in accessing medicines.

A Pharma Wholesaler Scorecard

Amid the topsy-turvy developments in global trade, one message appears certain for pharma manufacturers: the escalating need to stockpile inventory in the US.

The Tariff Saga Continues

In the second part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, outlines how the impact of a steep pharmaceutical import tariff varies across raw materials, components, and finished products, along with why such a policy could incentivize companies to shift production to the US.

How a 250% Tariff Might Ripple Through Pharma Supply Chains and Spur Domestic Production

Two Labs’ Michael Rowe assesses the industry’s level of preparation, including challenges stakeholders have encountered along the way. 

DSCSA Compliance Has Arrived. Now What?

The directive calls for building a six-month Strategic Active Pharmaceutical Ingredients Reserve, updating the essential medicines list, and prioritizing US-made APIs.

Trump Executive Order Targets Domestic API Stockpile to Strengthen US Pharmaceutical Supply Chain

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well. 